Cyclin E as molecular marker in the management of breast cancer: a review

Anal Quant Cytol Histol. 2006 Apr;28(2):111-4.

Abstract

Over the past decade numerous molecular markers have been identified that may play a role in breast carcinogenesis and prognosis. The most commonly used markers in clinical practice are the estrogen receptor, progesterone receptor and HER-2/neu. Recent studies found cyclin E to be a promising prognostic indicator in breast cancer and examined its potential as a target for therapy. Further studies demonstrated that cyclin E levels were periodic during the cell cycle, with levels of protein peaking in the G1 phase. This peak in cyclin E levels also correlated with maximum enzymatic function of the cyclin E-cdk2 complex, suggesting a critical role of cyclin E in regulating G1 to S-phase transition. Studies examining the relevance of cyclin E alterations in breast cancer have shown gene amplifications in some breast cancer cell lines, data that provide strong support for the role of cyclin E in breast carcinogenesis. It is believed that the most significant cyclin E alteration is post-translational cleavage of full-length cyclin E into low molecular weight forms that are hyperactive compared to the 50-kDa, full-length protein and correlate with increasing stage and grade of breast cancer. The role of cyclin E in the prognosis and therapy of breast cancer is reviewed according to recent publications.

Publication types

  • Review

MeSH terms

  • Biomarkers / analysis
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / therapy
  • Cyclin E / analysis*
  • Cyclin-Dependent Kinase 2 / metabolism
  • Disease Progression
  • Female
  • Humans
  • Pancreatic Elastase / antagonists & inhibitors
  • Prognosis
  • Survival Analysis

Substances

  • Biomarkers
  • Cyclin E
  • Cyclin-Dependent Kinase 2
  • Pancreatic Elastase